menu
    • menu
    [{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Nitrofurantoin","moa":"30S ribosomal S10","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitrofurantoin","moa":"30S ribosomal S10","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"CNX Therapeutics","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"Nitrofurantoin","moa":"30S ribosomal S10","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CNX Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"CNX Therapeutics \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"CNX Therapeutics \/ Adalvo"},{"orgOrder":0,"company":"Nostrum Laboratories","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Acquisition","leadProduct":"Nitrofurantoin","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nostrum Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Nostrum Laboratories \/ Strides Pharma Science","highestDevelopmentStatusID":"15","companyTruncated":"Nostrum Laboratories \/ Strides Pharma Science"}]

    Find Clinical Drug Pipeline Developments & Deals for urodil

    Menu

    urodil

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nostrum Laboratories

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            Nostrum Laboratories

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrofurantoin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Strides Pharma Science

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Strides Acquires Identified ANDAs from Nostrum Laboratories, USA

                            Details : The portfolio consists of liquids, including Nitrofurantoin, and immediate release solid orals to treat infections associated with UTIs, Pain Management, Allergy Symptoms, ADHD and Narcolepsy.

                            Product Name : Nitrofurantoin-Generic

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            May 03, 2025

                            Lead Product(s) : Nitrofurantoin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Strides Pharma Science

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CNX Therapeutics

                            United Kingdom arrow
                            China Battery Fair
                            Not Confirmed

                            CNX Therapeutics

                            United Kingdom arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrofurantoin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Adalvo

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            CNX and Adalvo Sign Deal for Nitrofurantoin PR Commercialization

                            Details : Through the partnership, Nitrofurantoin PR-Generic (nitrofurantoin), will be available in the UK as the first generic version. It is indicated for the treatment of acute uncomplicated UTIs.

                            Product Name : Nitrofurantoin PR-Generic

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            December 16, 2024

                            Lead Product(s) : Nitrofurantoin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Adalvo

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrofurantoin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP

                            Details : Nitrofurantoin is activated inside bacteria by reduction via the flavoprotein nitrofurantoin reductase to unstable metabolites, which disrupt ribosomal RNA, DNA and other intracellular components. It is bactericidal, especially to bacteria present in aci...

                            Product Name : Furadantin-Generic

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 24, 2023

                            Lead Product(s) : Nitrofurantoin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alembic Pharmaceuticals Limited

                            India arrow
                            China Battery Fair
                            Not Confirmed

                            Alembic Pharmaceuticals Limited

                            India arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrofurantoin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alembic Pharmaceuticals announces USFDA Final Approval for Nitrofurantoin Capsules, USP (Macrocrystals), 25 mg...

                            Details : Nitrofurantoin capsules, USP (Macrocrystals) is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella an...

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            January 07, 2021

                            Lead Product(s) : Nitrofurantoin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth